Thursday, June 24, 2010 - Novel targeting drugs & Radiotherapy


8.30 am	Opening ceremony
9.00 am	Introductive Lecture : Gillies McKenna, Director of the Radiation Oncology Gray Institute for Radiation Oncology & Biology, University of Oxford, UK. “Tumor Conditioning: A Novel Use of Signal Transduction Inhibitors."

9.45 am	Plenary session: Intracellular mechanisms of tumor radioresistance
9.45 am	Philip J. Tofilon, Department of Interdisciplinary Oncology, Drug Discovery Program, H. Lee Moffitt, Cancer Center and Research Institute, Tampa, USA "In vitro and in vivo radioresponse of glioblastoma stem-like cells"
10.30 - 11.15 am	Hans-Peter Rodemann, Division of Radiobiology and Molecular Environmental Research, Department of Radiation Oncology, University of Tuebingen, Germany "ErbR receptor signaling and control of DNA repair"

11.15 am	Coffee break

11.45 - 1.15	Oral communications

• Sebastien Guihard : The Amyloid ??Precursor Protein-Binding Protein 1 (APP-BP1) gene expression level modulates the radiosensitivity of Human head and neck squamous cell carcinoma cell lines through the neddylation pathway and is a promising therapeutic target.
• Conchita Vens : Exploiting base excision repair deficiencies for tumor-targeted radiosensitization.
• Marcel Verheij SHIP-1 down-regulation determines resistance to alkyl-lysophospholipid-, DNA damage- and FAS ligand-induced apoptosis in mouse lymphoma cells.
• Thierry Muanza : Apoptosis in Breast Cancer Cells Undergoing a Combined Administration of Novel Targeted Molecules and Radiation.
• Cyril Buhler : A multiscale comparison of the distribution of short dsDNA (DBAIT) complexed with polyethylenimine (PEI) or conjugated to cholesterol to sensitize tumor to radiotherapy.


1.15 pm	Lunch

2 - 3 pm	Roche Symposium Alfredo Zurlo, MD. Medical Director - Oncology, Roche France. "Roche’s Oncology Pipeline." Marc Chamberlain, MD. University of Washington - Seattle Cancer Care Alliance, Seattle, USA : "Angiogenesis inhibition and radiation therapy in glioma" Christopher Willett, MD. Duke University Medical Center, Durham, USA: "Angiogenesis inhibition and radiation therapy in GI cancers”
3 pm	Plenary session: Angiogenesis
3 pm	Dai Fukumura, Project Leader of E Steele Laboratory, Harvard, USA. "Targeting tumor microvasculature and microenvironment".
3.45 pm	Oriol Casanovas, Translational Research Laboratory, Catalan Institute of Oncology – IDIBELL, Barcelona, Spain “Evasive resistance to antiangiogenic therapies: from mechanisms to clinical relevance”

4.30 pm	Coffee break

4.45 - 6.15 pm	Oral communications

• Anthony Brade Preliminary results : a phase I study of Sorafenib and palliative radiation in patients with malignancy in the thorax, abdomen or pelvis.
• François Paris P38-mediated endothelial cell death after ionizing radiation is under the control of reactive reaction species, ceramide generation and membrane remodelling.
• Severine Planel FGFR1-induced radioresistance of Panc02 pancreatic tumor cells is decreased by SSR128129 treatment in vitro and in vivo.
• Alexandra Benouaich-Amiel Bevacizumab and irinotecan in recurrent high grade glioma: a retrospective monocentric study. • Christine Toulas Targeting FGFR-1 pathways by the antagonist SSR128129E overcomes the radioresistance of human glioma in vitro and in vivo.


7.30 pm	Evening reception, Restaurant le 19